With a simple saliva sample, the new comprehensive hereditary prostate cancer test offering provides insights into a patient’s risk of developing cancer, disease progression, and response to prostate cancer therapies. Germline testing of prostate cancer patients is recommended in the National Comprehensive Cancer Network (NCCN) guidelines and is covered by Medicare and many commercial insurance plans, for eligible patients.

Michael K. McGarrity, CEO of mdxhealth, commented: “The addition of this test to our menu reflects our commitment to delivering clinically actionable precision diagnostics to our urology customer base, providing both clinicians and patients with insights into the diagnosis and treatment of prostate cancer, particularly where genetic factors play a critical role. Given the established clinical guidelines and reimbursement, we believe this portfolio addition will contribute to revenue and growth in the second half of this year.”

Prostate cancer remains a leading cause of cancer-related death among men, with an estimated 288,300 new diagnoses and 34,700 deaths annually. Decades of research indicate that prostate cancer has a strong genetic component with implications to ancestry.